well-tolerated

Pompe disease treatment MZE001 shows promise in Phase 1 trial

Single and multiple ascending doses of MZE001, Maze Therapeutics‘ experimental oral substrate reduction treatment for Pompe disease, were well tolerated and reduced glycogen levels in healthy volunteers in a Phase 1 trial, data show. These findings support a Phase 2 trial of MZE001 in people with Pompe disease,…

Oral Therapy MZE001 Well-tolerated in Healthy Volunteers in Trial

MZE001, an experimental oral substrate reduction treatment for Pompe disease, was well-tolerated in both single and multiple doses in a study conducted in healthy volunteers, according to Maze Therapeutics, the therapy’s developer. Based on the trial’s findings, Maze is planning to launch a new study in 2023 to…